Forma Therapeutics Holdings Inc
NASDAQ:FMTX
Intrinsic Value
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of FMTX.
Fundamental Analysis
Balance Sheet Decomposition
Forma Therapeutics Holdings Inc
Current Assets | 426.4m |
Cash & Short-Term Investments | 395.9m |
Receivables | 15.4m |
Other Current Assets | 15.2m |
Non-Current Assets | 48.7m |
PP&E | 35.9m |
Other Non-Current Assets | 12.8m |
Current Liabilities | 33.5m |
Accounts Payable | 3m |
Accrued Liabilities | 28.8m |
Other Current Liabilities | 1.7m |
Non-Current Liabilities | 27.2m |
Other Non-Current Liabilities | 27.2m |
Earnings Waterfall
Forma Therapeutics Holdings Inc
Revenue
|
0
USD
|
Operating Expenses
|
-191.1m
USD
|
Operating Income
|
-191.1m
USD
|
Other Expenses
|
970k
USD
|
Net Income
|
-190.2m
USD
|
Free Cash Flow Analysis
Forma Therapeutics Holdings Inc
What is Free Cash Flow?
FMTX Profitability Score
Profitability Due Diligence
Forma Therapeutics Holdings Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Forma Therapeutics Holdings Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
FMTX Solvency Score
Solvency Due Diligence
Forma Therapeutics Holdings Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Forma Therapeutics Holdings Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FMTX Price Targets Summary
Forma Therapeutics Holdings Inc
Ownership
FMTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
FMTX Price
Forma Therapeutics Holdings Inc
Average Annual Return | -13.69% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -90% |
Market Capitalization | 957.2m USD |
Shares Outstanding | 47 860 400 |
Percentage of Shares Shorted | 3.31% |
FMTX News
Last Important Events
Forma Therapeutics Holdings Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Forma Therapeutics Holdings Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 166 full-time employees. The company went IPO on 2020-06-16. The firm is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.